Bausch Health Companies Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical and medical device company focused on developing, manufacturing and marketing a diverse portfolio of products. The company’s heritage dates back to the founding of ICN Pharmaceuticals in 1959, and it adopted the Bausch Health name in 2018 to reflect its leading eye health franchise, Bausch + Lomb, which it acquired in 2013.
The company operates through two primary business segments: Pharmaceuticals and Eye Health. In its Pharmaceuticals segment, Bausch Health offers prescription therapies in areas such as dermatology, neurology, gastroenterology and branded respiratory treatments. The Eye Health segment, led by the Bausch + Lomb brand, includes a range of surgical, contact lens, and ophthalmic pharmaceutical products designed to address conditions like dry eye, cataracts, glaucoma and retinal diseases.
Bausch Health serves patients, healthcare professionals and retailers in more than 100 countries across North America, Europe, Latin America, Asia-Pacific and the Middle East. The company maintains research and development centers in key markets and collaborates with academic institutions and industry partners to advance clinical programs and bring new therapies to market. Its global manufacturing footprint includes sites in the United States, Canada, Ireland, the Netherlands and Asia.
Under the leadership of President and Chief Executive Officer Joseph C. Papa, Bausch Health has prioritized strengthening its core franchises, optimizing its product pipeline and improving operational efficiency. The company’s executive team combines experience in pharmaceuticals, ophthalmology and global supply chain management, guiding strategy with a focus on innovation, strategic acquisitions and expanding access to care for patients worldwide.
